Mantle Cell Lymphoma (MCL)
Conditions
Brief summary
Progression-free survival. This is defined as the interval between date of obtaining informed consent and date of documented progression, first relapse, or death of any cause. Otherwise, patients will be censored at the last date they were known to be alive.
Detailed description
Complete response rate at 6 months, Molecular remission rate (MRR) by PCR, Overall response rate, Progression-free survival (median), Response duration (median), Duration of molecular remission (median), Overall survival (median), CR, MRR and ORR in TP53-mutated MCL, Safety, in terms of all grade 3-5 AE
Interventions
DRUGACALABRUTINIB
Sponsors
Region Skane
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival. This is defined as the interval between date of obtaining informed consent and date of documented progression, first relapse, or death of any cause. Otherwise, patients will be censored at the last date they were known to be alive. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete response rate at 6 months, Molecular remission rate (MRR) by PCR, Overall response rate, Progression-free survival (median), Response duration (median), Duration of molecular remission (median), Overall survival (median), CR, MRR and ORR in TP53-mutated MCL, Safety, in terms of all grade 3-5 AE | — |
Countries
Denmark, Finland, Norway, Sweden
Outcome results
None listed